GlassScriptPhysician profile
Douglas Howard
NPI 1225471790
$1,985.21
in general payments reported to CMS, 2019-2025
23 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.04 · 2020: $182 · 2021: $215 · 2022: $443 · 2023: $638 · 2024: $227 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.30 | 2020-2023 | |
| Astellas Pharma US INC | $250.30 | 2022-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $198.66 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $175.27 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $122.59 | 2022-2025 | |
| Shield Therapeutics INC | $105.25 | 2022-2024 | Accrufer |
| Myovant Sciences INC. | $99.34 | 2021-2022 | |
| Therapeuticsmd, INC. | $92.93 | 2022 | |
| Indivior INC. | $86.44 | 2020 | |
| Exeltis, USA INC. | $80.76 | 2022-2025 | Slynd, Tyblume |
| Hologic Sales and Service, LLC | $65.29 | 2023-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Fluent Fluid Management System |
| Gynesonics, INC. | $60.86 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Merck Sharp & Dohme LLC | $57.41 | 2020-2024 | Gardasil 9, Gardasil |
| Meditrina | $44.43 | 2023-2025 | |
| Exact Sciences Corporation | $40.28 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $36.06 | 2022-2023 | Twirla |
| Novo Nordisk INC | $28.91 | 2020-2022 | |
| Millicent US INC | $18.81 | 2025 | Femlyv |
| Daiichi Sankyo INC. | $16.72 | 2021 | |
| Minerva Surgical, INC | $13.93 | 2023 | |
| Baxter Healthcare | $13.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.14 | 2021 | |
| Gilead Sciences, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.